ANTH News Alert Anthera Pharmaceuticals (ANTH) 1.77 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Anthera Pharmaceuticals (ANTH) 1.77 $ANTH

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:12AM CST

FRO: 2.29 (-0.58), TLM: 7.58 (+2.46), SPHS: 0.45 (-0.07), HGSH: 4.67 (-0.90), SN: 7.15 (+0.67), NBG: 1.80 (-0.03), AXAS: 2.66 (+0.10), RVBD: 20.28 (-0.03), OPK: 8.70 (-0.16), ANTH: 1.77 (-0.10), ONVO: 6.29 (-0.24), KEG: 1.05 (-0.08), CALA: 26.32 (-0.43), XCO: 2.16 (+0.05), CRUS: 22.89 (-0.07), ARCP: 7.70 (-0.53)

Anthera Pharmaceuticals Licenses Japan Rights for Blisibimod to Zenyaku Kogyo Co., Ltd.
PR Newswire - Mon Dec 15, 8:00AM CST
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that Anthera and Zenyaku Kogyo Co., Ltd. of Tokyo, Japan executed an exclusive license agreement for the development and commercialization of subcutaneous blisibimod in Japan and potentially other countries throughout Asia. Anthera retains full development and commercialization rights for all other global territories including North America and the European Union. Zenyaku currently markets Rituxan(TM), an anti-CD20 antibody, in Japan where it is approved for CD20 Positive B-Cell Lymphoma, B-cell Lymphoproliferative disorder, ANCA associated vasculitis (GPA, MPA), and Pediatric Nephrotic Syndrome.
ANTH: 1.77 (-0.10)

Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 14.34 (-0.03), BIIB: 325.13 (-10.67), IMMU: 4.23 (+0.02), RDHL: 10.75 (-1.41), AMGN: 159.44 (-0.16), LLY: 69.26 (-0.41), GSK: 41.92 (+0.62), ARGS: 8.93 (+0.49), NVO: 43.29 (-0.35), IDRA: 3.59 (+0.13), ANTH: 1.77 (-0.10), MRK: 56.80 (-0.15), CBMG: 12.84 (-0.75), CELGZ: 3.29 (-0.18)

Wegener's Granulomatosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 3:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/q4wq75/wegeners) has announced the addition of the "Wegener's Granulomatosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wegener's Granulomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener's Granulomatosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Wegener's Granulomatosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wegener's Granulomatosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Anthera Pharmaceuticals - Aprogen - ChemoCentryx. - Epirus Biopharmaceuticals - Panacea Biotec - Pharmapraxis - Sandoz For more information visit http://www.researchandmarkets.com/research/q4wq75/wegeners
ANTH: 1.77 (-0.10)

Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
PR Newswire - Sun Nov 23, 8:30PM CST
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update at the 2014 Annual Piper Jaffray Healthcare Conference.
ANTH: 1.77 (-0.10)

Anthera & Patheon signs manufacturing agreement for Liprotamase Phase III Registration Trial
M2 - Fri Nov 21, 5:55AM CST
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) announced on Thursday that it has entered in a manufacturing and supply agreement for Sollpura with the Patheon division of DPx Holdings BV.
ANTH: 1.77 (-0.10)

Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
PR Newswire - Thu Nov 20, 10:00AM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) announced today it has signed a manufacturing and supply agreement with the Patheon® division of DPx Holdings B.V. The contract provides for Patheon to support the production of the Sollpura® clinical drug product for Anthera's Phase III registration trial (SOLUTION - see below).
ANTH: 1.77 (-0.10)

Anthera Pharmaceuticals beats by $0.08
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 3:53PM CST

ANTH: 1.77 (-0.10)

Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update
PR Newswire - Fri Nov 14, 3:05PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the third quarter ended September 30, 2014.
ANTH: 1.77 (-0.10)

Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.78 (+0.14), PCYC: 129.56 (+1.12), CLDX: 16.83 (-0.05), INCY: 71.62 (-0.52), BIND: 5.56 (+0.01), CELG: 110.09 (-1.79), OMER: 20.51 (-0.62), VSTM: 8.20 (+0.01), GILD: 100.46 (-2.70), OGXI: 2.25 (+0.03), ANTH: 1.77 (-0.10), NVAX: 5.60 (-0.03)

Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions for Blisibimod
PR Newswire - Wed Oct 01, 3:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
ANTH: 1.77 (-0.10)

4 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Oct 01, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
ROIAK: 1.50 (+0.03), ANTH: 1.77 (-0.10), TRXC: 1.50 (+0.04), SYMX: 0.90 (-0.01)

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 15.91 (+0.33), GILD: 100.46 (-2.70), ANTH: 1.77 (-0.10), QGEN: 22.39 (-0.08)

Genomic Health Upbeat on Strong International Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 2:00PM CDT
Genomic Health (GHDX) is focused on delivering revenue growth through constant investment for higher adoption of its tests across three major cancers
CBM: 23.35 (+0.01), GILD: 100.46 (-2.70), ANTH: 1.77 (-0.10), GHDX: 30.54 (+0.01)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ARC: 9.05 (-0.03), BIDU: 219.96 (-5.85), ANTH: 1.77 (-0.10), AMGN: 159.44 (-0.16), ALSN: 33.08 (-0.54)

Market Maker Surveillance Report. PDLI, AT, ISNS, QLTI, SINO, ANTH, Losing Stocks With Lowest Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:31AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. PDL Biopharma Inc (NASDAQ DLI), ATLANTIC POWER CORP (NYSE:AT), Image Sensing Systems Inc (NASDAQ:ISNS), QLT INC (NASDAQ:QLTI), Sino-Global Shipping America Ltd (NASDAQ:SINO), Anthera Pharmaceuticals Inc (NASDAQ:ANTH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AT: 2.47 (+0.09), QLTI: 3.41 (-0.03), ANTH: 1.77 (-0.10), ISNS: 2.36 (-0.09), SINO: 1.55 (-0.11), PDLI: 7.32 (-0.07)

Anthera (ANTH) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 9:41AM CDT
Anthera (ANTH) Enters Oversold Territory
ANTH: 1.77 (-0.10)

Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 8:31AM CDT
Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy?
ANTH: 1.77 (-0.10)

Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
PR Newswire - Mon Jul 28, 4:40PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014.
ANTH: 1.77 (-0.10)

The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
ANTH: 1.77 (-0.10), AMGN: 159.44 (-0.16), LLY: 69.26 (-0.41)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 110

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 93

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 167

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 118

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 162

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 165

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 205

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 87

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Avaline's Organic Wines Shine in New Holiday Campaign

Updated Category News Views 250

Avaline Unveils Its Charming Holiday Campaign The organic wine brand Avaline is excited to kick off its holiday campaign, which beautifully captures the spirit of the season. By blending nostalgia with festive cheer, Avaline invites everyone to relish the little moments that make the holidays special. The campaign draws inspiration from beloved holiday films, reminding us...

Continue Reading
Exploring In-Game Advertising: Key Insights for Brands

Updated Category News Views 206

Unlocking the Potential of In-Game Advertising Recent research conducted by Cint sheds light on the rising value of in-game advertising (IGA) for brands and the necessity for measurement standards within this dynamic marketing field. Video games have increasingly become a vital platform for advertisers, offering rich engagement opportunities. Consumers are showing...

Continue Reading
Mawson Infrastructure Reports Significant Operational Growth

Updated Category News Views 66

Update on Mawson Infrastructure Group's Operations Mawson Infrastructure Group Inc. recently released a significant operational update that highlights impressive growth in its digital colocation sector. The figures show a remarkable 166% increase in digital colocation revenue compared to a year ago, specifically in August 2023, and a solid 25% growth from the previous...

Continue Reading
Cybersecurity Landscape Evolves: New Threats and Insights

Updated Category News Views 292

An Overview of Current Cybersecurity Threats The digital landscape is becoming increasingly complex, and organizations are challenged with new and emerging cybersecurity threats. Red Canary's recent report dives deep into these threats, highlighting alarming trends that security teams must address now. The Rise of Identity Attacks As technology continues to advance, so do...

Continue Reading
US Family Health Plan Brighton Marine Celebrates Recognition with Awards

Updated Category News Views 188

US Family Health Plan Brighton Marine Honored with Excellence Awards Recent accolades reflect the dedication and quality of care provided by US Family Health Plan Brighton Marine. This esteemed organization has been awarded three Human Experience Pinnacle of Excellence Awards, recognizing it as one of the top health plans across the nation. Such recognition highlights the...

Continue Reading